Shields Clinical Outcomes Report
2024
Get in touch
DIsease States
Shields Care Model
Future Outlooks
Overview
01
02
03
04
05
01
02
03
04
05
scrolL
Health System Partners
80+
Quick Facts
At Shields, we are more than just a provider of solutions – we are subject matter experts and pioneers in specialty pharmacy integration.
By partnering with the industry’s foremost leaders and employing an integrated care model founded on innovation and compassion, we work side by side with our partners to accelerate the success of their specialty pharmacy programs.
Our Company
At Shields Health Solutions, we know that managing complex conditions requires more than just medication—it demands a seamless, patient-centered approach to care. Our integrated specialty pharmacy care model removes barriers that often disrupt or fragment patient care, ensuring that individuals receive the specialty medications they need without unnecessary delays.
By leveraging a dedicated team of clinical pharmacists, liaisons, and patient support advocates, we engage directly with patients and their families to provide education, coordinate care, and navigate challenges. This high-touch, collaborative model not only drives better clinical outcomes but also enhances system-wide performance for our health system partners.
Complex Care, Simplified
02 Shields Care Model
It starts with our people—some of the most experienced, hardworking, and dedicated professionals in the industry. But what truly sets us apart is how we harness data.
At Shields, we leverage advanced analytics across a vast spectrum of clinical data, setting new benchmarks for healthcare insights. Our approach integrates data from multiple sources—including electronic health records, patient-reported outcomes, and pharmacy dispensing records—into a unified platform designed exclusively for Shields. This powerful data infrastructure allows us to develop robust clinical outcome measures that not only meet but exceed industry quality standards.
But having data is just the beginning—it's how we use it that makes the difference. Our customizable reports and real-time dashboards empower healthcare professionals to pinpoint areas for improvement, track performance trends, and make informed, data-driven decisions that enhance patient care. From clinicians to operations leaders, every team member has the tools to uncover opportunities, monitor progress, and refine healthcare delivery—focusing on key metrics that drive quality and optimize patient outcomes.
This is why not all outcomes reports are created equal—because not all specialty pharmacy accelerators are built like Shields.
What Makes the Shields Care Model So Unique?
Discover how our integrated and comprehensive offerings improve therapy management and care coordination for patients with chronic and complex diseases.
Achieving Quality Clinical Outcomes
03 Disease States
04 future Outlook
Fill out the form to get in touch with our clinical outcomes team to learn more about Shields outcome offering.
When You're Ready for More
05 Get In Touch
Hospitals & Clinics
1,000+
Patients Served
1.6M
Payer Access Secured
~90%
Drug Access Secured
~90%
in Financial Assistance Secured 2024
2.3B
in Cost Avoidance
>$2M
Copyright | Privacy Policy
Tracking Universal Outcomes
Treatment effectiveness & clinical response
Healthcare resource utilization
Medication adherence & management
Patient-reported outcomes
Clinical interventions & lab results
Quality of life
We Provide Specialized Monitoring for the Following Disease-specific Analytics
Autoimmune Conditions
Rare Diseases
Oncology
Neurology
Hematology
And 20+ More Therapeutic Areas
Reduction in Total Cost of Care
13%
Average Time on Service
5 Yrs
Shields
Care Model
Coordinate
Enhance
Renew
Intervene
Engage
Engage
Our team engages with patients at the clinic and through telephonic appointments to educate them on the importance of therapy adherence and completing routine lab work.
>1M
FAs/PAs Completed
Intervene
<2 days
Average Time to Therapy
Clinical pharmacists provide side effect mitigation tactics, monitor for drug interactions, and analyze lab results to optimize medication therapy.
Coordinate
$2.3B
Financial Assistance Secured in 2024
Our team investigates patient insurance benefits, completes prior authorizations, and identifies financial assistance opportunities so patients and providers can focus on their health, not paperwork.
Renew
91%
Average Provider Score
Ongoing interactions beyond refills; our experts provide ongoing education, proactively identify opportunities to monitor and improve patient care and outcomes at each touchpoint.
Enhance
92%
Average Medication Adherence
Through pharmacist, liaison and other interventions, our team can enhance patient care, provide emotional support, and help educate and coordinate care.
Click each section to explore how our dedicated clinical team of pharmacists, liaisons, and patient support advocates work to eliminate disruptions that derail or fragment patient care, driving superior outcomes and elevating system-wide performance.
At Shields, we take immense pride in leading the charge to deliver exceptional patient care through our strategic partnerships with health systems. Our goal is simple: to ensure every patient achieves the best possible outcomes from their medication therapy.
Our commitment to enhancing patient health is driven by a state-of-the-art data analytics engine, which powers our innovative integrated care model. This model provides the insights necessary to continuously refine our approach and allow us to engage swiftly with the most vulnerable patients. Health equity is at the core of everything we do, ensuring that all patients, no matter their background or circumstances, have access to the care they need. We understand that achieving optimal patient outcomes requires a personalized approach—one that addresses the unique challenges of diverse patient populations while promoting accessibility and inclusion across healthcare.
The success of our patient outcomes is built on a collaborative strategy, where our clinicians work closely with both providers and patients. By integrating pharmacists as vital members of the healthcare team, we foster meaningful relationships that allow us to intervene early, optimizing patient outcomes and enhancing the overall healthcare experience.
As we look to the future, we embrace rapid advancements in technology and data analytics. These innovations empower us to more accurately anticipate patient needs and implement proactive interventions that drive improved outcomes. Our commitment to continuous improvement ensures that we remain at the forefront of an ever-evolving healthcare landscape.
At the heart of our mission is a simple but powerful belief: patients are our "why." Every individual deserves personalized, equitable care tailored to their unique needs. In partnership with our healthcare providers and the broader community, we are dedicated to raising the standard of specialty pharmacy and ensuring that every interaction contributes to better health outcomes today and lays the foundation for a healthier tomorrow.
Vice President of Clinical Services
Our Company
Our History
Our Team
Our History
Our Team
Founded in 2012, Shields was born from a vision to transform specialty pharmacy care through collaboration with hospitals and health systems. Established by a team of healthcare experts, we refined the integrated care model by combining clinical pharmacy services with health system operations. Over the years, we have grown significantly, forming strategic partnerships with leading health systems across the country.
Our history
The Clinical Outcomes Team at Shields Health Solutions is integral to demonstrating the value of our integrated care model through the development, implementation, analysis, and validation of patient outcomes. Comprising clinical specialists with deep expertise in specialty pharmacy, this team employs a data-driven approach to evaluate metrics that highlight the effectiveness of our care strategies. Their efforts focus on actionable insights regarding medication adherence, treatment efficacy, and patient satisfaction, ultimately informing patient care pathways and strategic decision-making.
Our team
Multiple Sclerosis (MS)
Reducing the number of flares over time can delay the progression of disability and neurologic dysfunction.2 If a patient reports a relapse, our pharmacists will evaluate the EMR to determine if the event could be due to medication-related concerns, such as non-adherence. Pharmacists can intervene with the patient and provider to resolve any medication issues and coordinate care to address the relapse. Measuring absenteeism and adherence is crucial in identifying gaps in care, ensuring timely interventions, and improving overall health outcomes.
Why It Matters
We track universal and disease-specific metrics to enhance patient care and support data-driven decision-making. By focusing on quality improvement, value-based care, population health management, and cost optimization, we leverage advanced data capabilities to provide real-time analytics, custom reporting, risk stratification, and population health insights for continuous improvement.
Download PDF
What We Measure
Patient Reported Treatment Efficacy
Adherence**
Of patients receive and take medications on time
Of patients report feeling very well or well about how their specialty medication is working
94%
80%
Benchmark3-6
**Average number of patients reported flares in one year
Optimal Annualized Relapse Rate (ARR)**
94%
0
0.1
0.2
0.3
0.4
Optimal ARR
Shields Health Solutions
MS is a chronic, autoimmune disease of the central nervous system, affecting the communication between the brain and other parts of the body. While there is currently no cure for MS, establishing and following a treatment plan is the best way to manage the disease and enhance quality of life.
Treatment plans often include medications to prevent the number of relapses and help treat symptoms.1
0.18
≤0.372
View MS References
Many specialty pharmacy medications are costly, have high copayments, limited insurance coverage, and involve multiple prior authorization steps. Additionally, patients facing high out-of-pocket expenses are more likely to discontinue therapy.
Common Barriers to Treatment
Financial Burden
Coordination of care between patients and multiple providers is often insufficient. Many treatment regimens involve medications with significant side effects and necessitate frequent monitoring, making seamless care coordination essential but frequently lacking.
Inadequate Care Coordination
Patients may experience social isolation or inadequate support from family and friends, which can impact their ability to cope with and adhere to treatment plans.
Social Isolation & Lack of Support
Explore our latest insights
The goal of treatment is to prevent the progression of the disease and to achieve SVR, a marker of the cure for Hepatitis C, meaning that the virus is no longer detectable in the blood 12 weeks after the patient completed treatment. Completing the full HCV treatment course is critical to cure the infection, eliminate the potential for transmission, improve quality of life, and avoid serious liver damage or even death. If SVR response is not achieved, getting the patient on the optimal therapy is key to preventing complications.2 Measuring absenteeism and adherence is crucial in identifying gaps in care, ensuring timely interventions, and improving overall health outcomes.
Why It Matters
Adherence**
Of patients receive and take medications on time
96%
Treatment Completion Rate
0
100%
Shields Network
96%
≥95%5-7
What We Measure
View Hep C References
Download PDF
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) and is spread through contact with the blood of an infected person. HCV infection is treated with medications intended to clear the virus from the body. These antiviral medications are highly effective and cure on average 95% of patients after 8-12 weeks of treatment.1, 2
Hepatitis C
Sustained Virologic Response Rate
Patients managing complex conditions often face significant barriers that delay or disrupt their treatment. These challenges not only impact adherence but also lead to worsening health outcomes. Addressing these obstacles requires an integrated approach that streamlines care, reduces delays, and ensures patients receive the right medication at the right time.
A lack of understanding regarding the progression of their condition can prevent patients from fully engaging in or adhering to their prescribed treatment plans.
Limited Understanding of Disease Progression
Patients often struggle with adhering to complex medication regimens, which is critical to preventing complications and maintaining treatment efficacy.
Challenges with Medication Adherence
Geographic constraints, financial limitations, inadequate insurance coverage, high copayments, and limited availability of specialized providers and facilities can make accessing essential care and medications difficult.
Barriers to Accessing Specialized Care
Emotional and mental health challenges, including stress, anxiety, and depression, can obstruct treatment adherence and overall disease management. Patients with robust support systems tend to achieve better outcomes, highlighting the importance of emotional and social support throughout the treatment journey.
Psychosocial Challenges
Learn more
90%
Benchmark8-10
Benchmark
87%
Benchmark
3,4
96%
Shields
Measuring disease activity and patient response enables healthcare teams to evaluate the success of RA treatments and identify needed changes. These scores support a collaborative effort among the patient care team, facilitating shared decisions to improve patient health outcomes. Tools like RAPID3, supplemented by patient-reported outcomes (PROs), provide valuable insights into disease management from patients’ perspectives. This contributes to a holistic understanding of patient experiences, ensuring optimum patient care and enhancing patient outcomes. Measuring absenteeism and adherence is crucial in identifying gaps in care, ensuring timely interventions, and improving overall health outcomes.
Why It Matters
Of patients receive and take medications on time
80%
Benchmark2-5
92%
Adherence**
Of patients reported no missed days of planned activity, school, or work
79%
No Absenteeism
What We Measure
View RA References
Download PDF
Rheumatoid Arthritis (RA) is an autoimmune and inflammatory disease in which the immune system attacks healthy cells, causing inflammation and painful swelling in the affected parts of the body.1
Management of RA includes a combination of clinician exams, laboratory work, and various combinations of medications that help slow disease progression and prevent joint deformity. This management approach plays a vital role in determining disease severity and achieving low disease activity or near remission with few or no RA symptoms, which is the goal of therapy.1
Rheumatoid
Arthritis (RA)
Disease Control
96%
of patients reported their condition has improved or has been stable since onboarded with Shields
Disease Activity
of RA patients IMPROVED their RAPID3 score, resulting in positive treatment outcomes
61%
Keeping a patient's viral load low is essential in helping them live longer, healthier lives while also reducing their chances of transmitting the virus to others. To maintain a low viral load, patients must adhere to ART and keep up with routine appointments. Nonadherence to ART may reduce treatment response, increase drug resistance and morbidity, and even result in death.10 Assessment of viral load suppression on an annual basis is a core performance measurement for patient qualification in the Ryan White & Global HIV/AIDS Program.11 Measuring absenteeism and adherence is crucial in identifying gaps in care, ensuring timely interventions, and improving overall health outcomes.
Why It Matters
Of patients receive and take medications on time
90%
Benchmark5-9
93%
Adherence**
Of patients report feeling very well or well about how their specialty medication is working
94%
Patient Reported Treatment Efficacy
Average % of patients
who reach viral supression
65%
What We Measure
View HIV References
Download PDF
Human immunodeficiency virus (HIV) is a virus spread through contact with certain fluids of an infected person, attacking the immune system and affecting the body's ability to fight infections and certain cancers. HIV is incurable and can progress to the most advanced disease stage if left untreated, known as Acquired Immunodeficiency Syndrome (AIDS).1 With proper medical care and a potent combination of antiretroviral therapy (ART), HIV has become a manageable chronic condition. ART therapy has proven to reduce health complications associated with the disease, increase life expectancy and prevent transmission.2
HIV
of HIV Viral Load Labs
completed on time
88%
93%
SHIELDS
National Average3
89.6%
Ryan White HIV/AIDS4
>66K
Clinical
Interventions
Average Patient Copay
$10
Patient Net Promoter Score
83
Even though corticosteroids are an effective induction treatment for IBD, they should not be used as a maintenance therapy due to the risk of dependency and a great deal of established side effects. Steroids may be used to stop flares, a systemic inflammation that may lead to progressive and irreversible intestinal damage. In children, persistent inflammation is associated with impairment of growth and pubertal development, risking permanent loss of height.4 IBD presents a significant burden on daily life activities and is associated with absence from work or school (absenteeism).5 In addition to corticosteroids and flares, measuring absenteeism and adherence is crucial to identifying gaps in care, ensuring timely interventions, and improving overall health outcomes.
Why It Matters
Of patients receive and take medications on time
80%
Benchmark2,3
90%
Adherence**
Of patients reported no missed days of planned activity, school, or work
89%
No Absenteeism
of patients reported using Corticosteroids at follow-up
9%
Corticosteroids
of patients do
not report flares
71%
Disease Flares
What We Measure
View IBD References
Download PDF
Inflammatory bowel disease (IBD) is a chronic, progressive disease caused by an abnormal mucosal immune response against intestinal microorganisms in genetically predisposed hosts. IBD is an umbrella term for Crohn's disease and ulcerative colitis. Treatment is based on the disease severity, and goals include eliminating symptoms, preventing surgery and other complications, minimizing the adverse effects of medications, and restoring quality of life.1
Inflammatory Bowel Disease
Of patients report feeling very well or well about how their specialty medication is working
93%
Patient Reported Treatment Efficacy
Transplant patients frequently require hospitalization or ER are due to comorbidities, rejection, infections from post-transplant immunosuppressant medications, and inadequate coordination between transplant centers and emergency providers. Regular follow-up, monitoring by clinicians, and adherence to anti-rejection medications can prevent some transplant-related hospitalizations and ER utilization. Monitoring hospital utilization provides insight into potential unmet healthcare needs and approaches to lower the total cost of medical care.10,11 Comprehensive care requires a thorough understanding of disease management. Absenteeism and adherence measurements are vital in providing insights into disease burden and quality of life effects, leading to enhanced care, improved quality of life, and reduced costs.
Why It Matters
Of patients receive and take medications on time
90%
Benchmark6-9
95%
Adherence**
Of patients reported no missed days of planned activity, school, or work
92%
No Absenteeism
Of patients report feeling very well or well about how their specialty medication is working
96%
Patient Reported Treatment Efficacy
What We Measure
View Transplant References
Download PDF
A transplant is a surgical procedure that transfers an organ, tissue, or cells from a donor to a recipient to replace damaged or failing body parts and restore health. Shields primarily follows patients with kidney, liver, heart, lung, pancreas, stem cell, and bone marrow transplants.
Transplant
Hospitalizations and Emergency Room (ER) Utilization
Percent of patients reporting unplanned ER visits or hospital stays
0
10%
20%
30%
50%
Benchmark
≤50%2-5
Shields
10%
40%
Pulmonary exacerbations are closely related to IV antibiotic use and hospitalizations and are a significant measure of disease severity. Acute pulmonary exacerbations are associated with rapid lung function decline, permanent loss of lung function, diminished quality of life, reduced survival, and increased healthcare costs.9 Decreasing the number of pulmonary exacerbations is a target in the care of CF patients. Measuring absenteeism and adherence is also crucial in identifying gaps in care, ensuring timely interventions, and improving overall health outcomes.
Why It Matters
Of patients receive and take medications on time
80%
Benchmark5-8
89%
Adherence**
Of patients reported no missed days of planned activity, school, or work
93%
No Absenteeism
Of patients report feeling very well or well about how their specialty medication is working
93%
Patient Reported Treatment Efficacy
What We Measure
View CF References
Download PDF
Cystic fibrosis (CF) is a genetic progressive disorder caused by mutations in the chloride ion channel cystic fibrosis transmembrane conductance regulator (CFTR), which helps to maintain the balance of salt and water on many surfaces in the body.
Many pharmacological treatments on the market address pulmonary manifestations of CF. However, oral CFTR protein modulators transformed the management of CF in the last decade.1 They are highly effective in most CF patients with eligible genotypes. CFTR modulators decrease pulmonary exacerbations, improve pulmonary function (ppFEV1), nutritional status, and respiratory health-related quality of life.2, 3
Cystic
Fibrosis
Pulmonary Exacerbations
Pediatric
<18 y/o
4%
Hospital and ER Utilization
Unplanned ER and hospital visits are common in cancer patients due to disease or drug complications, driving up care costs. Close clinical monitoring of patients on oral oncolytic therapy, especially early on, can help prevent these events by identifying adverse events, medication issues, and adherence barriers. Tracking absenteeism and adherence is key to addressing care gaps, enabling timely interventions, and improving health outcomes.
Why It Matters
Of patients receive and take medications on time
80%
Benchmark5-8
92%
Adherence**
Of patients reported no missed days of planned activity, school, or work
93%
No Absenteeism
See our proactive approach to the management of patients on complex oncology medications.
Shields Oncology
Patient Journey
SHIELDS:
Percent of patients reporting hospital and ER utilization due to oncology related symptoms
What We Measure
View Oncology References
Download PDF
Cancer, a genetic disease in which some of the body's cells grow uncontrollably and spread to other parts of the body, is caused by changes to genes that control the way our cells function.1 The goals of cancer treatment include eradicating known tumors, preventing the recurrence or spread of the primary cancer, and relieving symptoms.2
Oncology
Adult
≥18 y/o
7%
Of patients require ER visits or inpatient hospital stays fo CF
Shields Network
Benchmark4
0
21%
10%
20%
30%
7%
≤20%
≤25%
Pediatric
<18 y/o
Adult
≥18 y/o
4%
NATIONAL NETWORK
GROUP: ≤20%3,4
0%
10%
20%
View Patient Journey
Shields uses a proactive approach to the management of patients on complex oncology medications with a carefully designed cadence of clinical pharmacist assessments. Patients receive at least two clinical pharmacist touchpoints within the first week of therapy. Clinical reassessments depend on patient factors and medication risk; however overall, patients receive an average of three to 14 touchpoints annually, starting one week after therapy begins.
Shields Oncology Patient Journey
2
1
7
3
4
5
6
9
8
One week after starting medication
Before Starting Medication
Clinical reassessment every month to every
6 month depending
on the patient and medication factors
Months
Phamacist & Liaison Touchpoint
Liaison Touchpoint
PATIENT JOURNEY KEY
Integrated Disease States
50+
Jennifer L Donovan, PharmD
Authentic, compassionate connections drive shared success, ensuring every patient and partner thrives. We go beyond innovation—delivering real, measurable outcomes that improve patient health and reduce costs. More than just a continuum of care, we seamlessly guide health systems with expertise and empathy—because better care begins with genuine connections.
This report underscores the profound impact of our integrated specialty pharmacy model, highlighting an impressive 178% average annual growth in patient volume across diverse clinical programs—all while maintaining exceptional care outcomes. Our ability to scale without compromising quality reinforces the strength of our collaborative approach, setting new benchmarks for excellence in specialty pharmacy.
Driven by Unbeatable Clinical Outcomes
01 OVERVIEW
For the fourth consecutive year, we are excited to share our industry-leading outcomes across our expansive network of health system partners. At Shields, we are committed to empowering patients and health systems, transforming challenges into boundless opportunities.
Transplant
Cystic
Fibrosis
Inflammatory
Bowel Disease
HIV
Oncology
Rheumatoid
Arthritis
Hepatitis C
Multiple Sclerosis
“Multiple Sclerosis FAQ." National Multiple Sclerosis Society, https://www.nationalmssociety.org/What-is-MS/MS-FAQ-s#question-Can-MS-be-cured Accessed December 5, 2024.
Montalban X. Review of methodological issues of clinical trials in multiple sclerosis. J Neurol Sci. 2011; 311(Suppl. 1): S35–S42
Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23(8):844-852. doi:10.18553/jmcp.2017.23.8.844.
Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG. Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: a retrospective claims analysis. Neurol Ther. Published online January 12, 2022. doi:10.1007/s40120-021-00319-3.
Halpern R, Agarwal S, Dembek C, Borton L. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5:73-84. doi:10.2147/ppa.s15702.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. Available at: https://www.pqaalliance.org/assets/Measures/PQA_Measures_Overview.pdf.
Multiple Sclerosis References
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Hepatitis C Information. Centers for Disease Control and Prevention. Updated July 28, 2020. Accessed December 18, 2024. https://www.cdc.gov/hepatitis/hcv/index.htm
Hepatitis C. The World Health Organization. Updated July 27, 2020. Accessed December 18, 2024 https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Bolduc C, McCall K 3rd, Stickney K, Gelinas A, Levesque E. Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C. J Manag Care Spec Pharm. 2021;27(2):263-267. doi:10.18553/jmcp.2021.27.2.263. PMID: 33506724; PMCID: PMC10391126.
2022 pharmacy benefit management aggregate summary performance report. URAC. Published February 2023. Available at: https://www.urac.org/wpcontent/uploads/2023/02/URAC_PBM_Aggregate-Summary-Report_2022_FINAL_Feb-2023.pdf. Accessed May 1, 2024.
AASLD-IDSA. Treatment Guidelines. 2023 Update. https://www.hcvguidelines.org. Accessed April 25, 2024.
Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. Published online May 25, 2023:ciad319. doi:10.1093/cid/ciad319.
World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; April 9, 2024. Accessed April 25, 2024.
Yamamoto H, Ikesue H, Ikemura M, et al. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus-infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci. 2018;4(1):11. doi:10.1186/s40780-018-0113-3.
Younossi ZM, Stepanova M, Henry L, et al. Adherence to treatment of chronic hepatitis C: from interferon-containing regimens to interferon- and ribavirin-free regimens. Medicine (Baltimore). 2016;95(28):e4151. doi:10.1097/MD.0000000000004151.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. https://www.pqaalliance.org/assets/ Measures/PQA_Measures_Overview.pdf.
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Hepatitis C References
Rheumatoid Arthritis (RA) | Arthritis | CDC Accessed 12/14/24
Jin Y, Chen SK, Lee H, Landon JE, Merola JF, Kim SC. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. J Manag Care Spec Pharm. 2021;27(8):1106-1117. doi:10.18553/jmcp.2021.27.8.1106.
Zuckerman AD, Whelchel K, Kozlicki M, et al. Health-system specialty pharmacy role and outcomes: A review of current literature. Am J Health Syst Pharm. 2022;79(21):1906-1918. doi:10.1093/ajhp/zxac212.
Zuckerman AD, DeClercq J, Choi L, et al. Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies. Am J Health Syst Pharm. Published online August 18, 2021. doi:10.1093/ajhp/zxab342.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. Available at: https://www.pqaalliance.org/ assets/Measures/PQA_Measures_Overview.pdf.
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Rheumatoid Arthritis References
1 National Cancer Institute https://www.cancer.gov/about-cancer/understanding/what-is-cancer Updated May 5, 2021. Accessed December 14, 2024
National Cancer Institute. Seer Training Modules https://training.seer.cancer.gov/treatment/ Accessed Dec 14th, 2024.
Lash RS, Bell JF, Reed SC, et al. A systematic review of emergency department use among cancer patients. Cancer Nurs. 2017;40(2):135-144. doi:10.1097/NCC.0000000000000360.
Rivera DR, Gallicchio L, Brown J, et al. Trends in adult cancer-related emergency department utilization: An analysis of data from the Nationwide Emergency Department Sample. JAMA Oncol. 2017;3(10):e172450. doi:10.1001/jamaoncol.2017.2450.
Academia EC, Mejías-De Jesús CM, Stevens JS, et al. Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies. J Manag Care Spec Pharm. 2021;27(10):1438-1446. doi:10.18553/jmcp.2021.27.10.1438.
Doshi JA, Jahnke J, Raman S, et al. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries. J Manag Care Spec Pharm. 2021;27(10):1457-1468. doi:10.18553/jmcp.2021.27.10.1457.
Zuckerman AD, Whelchel K, Kozlicki M, et al. Health-system specialty pharmacy role and outcomes: A review of current literature. Am J Health Syst Pharm. 2022;79(21):1906-1918. doi:10.1093/ajhp/zxac212.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. Available at: https://www.pqaalliance.org/ assets/Measures/PQA_Measures_Overview.pdf.
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Oncology References
About HIV/AIDS | HIV Basics | HIV/AIDS | CDC Accessed 06.08.23 What Are HIV and AIDS? | HIV.gov Accessed 01.27.24
AdultandAdolescentGL.pdf (hiv.gov) Accessed 01.27.24 Treatment | Living with HIV | HIV Basics | HIV/AIDS | CDC Accessed 01.07.24
Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data- United States and 6 Dependent Areas, 2021. HIV Surveillance Supplemental Report 2024;28(4).
Health Resources and Services Administration. Ryan White HIV/AIDS Program Annual Data Report 2022. Published December 2023. Accessed January 11, 2024. https://ryanwhite.hrsa.gov/data/reports.
Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-366.
Komandt M, Canfield S, Lengel M, Gilmore V, Kilcrease C. Correlation between medication adherence using proportion of days covered and achieving viral suppression in patients living with HIV. J Manag Care Spec Pharm. 2023;29(10):1129-1137. doi:10.18553/jmcp.2023.29.10.1129.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
URAC. 2023 PBM Measures at a Glance. URAC. Published December 2022. Accessed October 4, 2024. Available at: https://www.urac.org/wp-content/uploads/2022/12/2023_PBM_Measures-at-a-Glance.pdf.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. Available at: https://www.pqaalliance.org/ assets/Measures/PQA_Measures_Overview.pdf.
Treatment Goals | NIH (hiv.gov) Accessed 06.08.23
1https://ryanwhite.hrsa.gov/data/reports. Published December 2023. Accessed January 11th, 2024
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
HIV References
Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015 Nov;169(11):1053-60. doi: 10.1001/jamapediatrics.2015.1982. PMID: 26414706; PMCID: PMC4702263.
Zuckerman AD, Whelchel K, Kozlicki M, et al. Health-system specialty pharmacy role and outcomes: A review of current literature. Am J Health Syst Pharm. 2022;79(21):1906-1918. doi:10.1093/ajhp/zxac212.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. Available at: https://www.pqaalliance.org/assets/Measures/PQA_Measures_Overview.pdf.
Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021 Jul;161(1):47-65. doi: 10.1053/j.gastro.2021.04.063. Epub 2021 April 30. PMID: 33940007; PMCID: PMC8640961.
Youssef M, Hossein-Javaheri N, Hoxha T, et. al. Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2024 Sep 3;18(9):1486-1504. doi: 10.1093/ecco-jcc/jjae057. PMID: 38647194; PMCID: PMC11369077.
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Inflammatory Bowel Disease References
Intro to CF. Cystic Fibrosis Foundation. https://www.cff.org/intro-cf#overview-of-cf. Accessed September 25, 2024.
Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65-124. doi:10.1016/S2213-2600(19)30337-6.
Ramos KJ, Pilewski JM, Taylor-Cousar JL. Challenges in the use of highly effective modulator treatment for cystic fibrosis. J Cyst Fibros. 2021 May;20(3):381-387. doi: 10.1016/j.jcf.2021.01.007. Epub 2021 January 30. PMID: 33531206; PMCID: PMC8192344.
Cystic Fibrosis Foundation Patient Registry. 2023 Annual Data Report Bethesda, Maryland ©2024 Cystic Fibrosis Foundation
Hansen CME, Breukelman AJ, van den Bemt PMLA, Zwitserloot AM, van Dijk L, van Boven JFM. Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review. Eur Respir Rev. 2024;33(173):240060. doi:10.1183/16000617.0060-2024.
Olivereau L, Nave V, Garcia S, et al. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France. J Cyst Fibros. 2020;19(3):402-406. doi:10.1016/j.jcf.2019.09.018.
Nasr SZ, Chou W, Villa KF, Chang E, Broder MS. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ. 2013;16(6):801-808. doi:10.3111/13696998.2013.787427.
PQA measure overview. Pharmacy Quality Alliance. Published 2024. Accessed October 21, 2024. Available at: https://www.pqaalliance.org/assets/Measures/PQA_Measures_Overview.pdf.
Goss CH. Acute Pulmonary Exacerbations in Cystic Fibrosis. Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 October 28. PMID: 31659730; PMCID: PMC7528649.
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Pediatric: < 18 years old Adult: ≥ 18 years old
Cystic Fibrosis References
Nelson J, Alvey N, Bowman L, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. Pharmacotherapy. 2022;42(8):599-633. doi:10.1002/phar.2716. PMID: 36032031.
Cserna J, Baumann CK, Lobmeyr E, et al. Emergency department utilization following allogeneic hematopoietic stem cell transplantation: a single-center retrospective longitudinal analysis of 557 patients. Transplant Cell Ther. 2023;29(5):321.e1-321.e9. doi:10.1016/j.jtct.2023.02.018.
Pothuru S, Chan WC, Goyal A, et al. Emergency department use and hospital admissions among adult orthotopic heart transplant patients. J Am Coll Emerg Physicians Open. 2022;3(3):e12718. doi:10.1002/emp2.12718.
Schold JD, Elfadawy N, Buccini LD, et al. Emergency department visits after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(4):674-683. doi:10.2215/CJN.07950715.
Unterman S, Zimmerman M, Tyo C, et al. A descriptive analysis of 1251 solid organ transplant visits to the emergency department. West J Emerg Med. 2009;10(1):48-54.
Chisholm-Burns M, Spivey C, Tolley E, Kaplan E. Medication therapy management and adherence among US renal transplant recipients. Patient Preference and Adherence. Published online April 2016:703. doi:https://doi.org/10.2147/ppa.s104646
Nevins TE, Nickerson PW, Dew MA. Understanding Medication Nonadherence after Kidney Transplant. Journal of the American Society of Nephrology. 2017;28(8):2290-2301. doi:https://doi.org/10.1681/asn.2017020216
Safia Boghani, Kirkham H, Witt EA, et al. Medication adherence and graft survival among heart transplant recipients. Journal of Drug Assessment. 2019;8(sup1):7-7. doi:https://doi.org/10.1080/21556660.2019.1658329
PQA measure overview. Pharmacy Quality Alliance. https://www.pqaalliance.org/assets/Measures/PQA_Measures_Overview.pdf. Published 2024. Accessed October 21, 2024. https://www.pqaalliance.org/measures-overview#pdc-dr
Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015. Epub December 20, 2022. PMID: 37080658.
Gandolfini I, Palmisano A, Fiaccadori E, Cravedi P, Maggiore U. Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation. Clin Kidney J. 2022;15(7):1253-1274. doi:10.1093/ckj/sfac017. PMID: 35756738; PMCID: PMC9217626
* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.
* All metrics are reflective of data collected in 2024
**Adherence is measured by the proportion of days covered (PDC)
Transplant References
% OF PATIENTS
View our
MS White Paper
View our Cystic Fibrosis White Paper
